FDC sarcomas
The enrichment in specific T-cell subsets prompted investigating the mRNA expression of the inhibitory immune receptor PD-1 and its ligands PD-L1 and PD-L2, which were found to be significantly upregulated in FDC sarcomas as compared with other mesenchymal tumors, a finding also confirmed<i>in situ</i>Here, it is demonstrated for the first time the transcriptional relationship of FDC sarcomas with nonmalignant FDCs and their distinction from other mesenchymal tumors.<b>Implications:</b>The current study provides evidence of a peculiar immune microenvironment associated with FDC sarcomas that may have clinical utility.<i>Mol Cancer Res; 15(5); 541-52.